ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 87 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5 | -50.0% | 897 | 0.0% | 0.00% | – |
| Q1 2024 | $10 | -64.3% | 897 | -52.1% | 0.00% | – |
| Q4 2023 | $28 | +180.0% | 1,871 | -9.0% | 0.00% | – |
| Q3 2023 | $10 | -33.3% | 2,055 | 0.0% | 0.00% | – |
| Q2 2023 | $15 | +66.7% | 2,055 | 0.0% | 0.00% | – |
| Q1 2023 | $9 | -69.0% | 2,055 | -19.5% | 0.00% | – |
| Q4 2022 | $29 | -99.9% | 2,553 | 0.0% | 0.00% | – |
| Q3 2022 | $24,000 | +14.3% | 2,553 | 0.0% | 0.00% | – |
| Q2 2022 | $21,000 | -57.1% | 2,553 | -11.9% | 0.00% | – |
| Q1 2022 | $49,000 | -79.0% | 2,898 | -8.1% | 0.00% | -100.0% |
| Q3 2021 | $233,000 | – | 3,155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |